ADA 2015 Investor & analyst event Boston, 7 June 2015 · 2020-04-17 · Slide 3 5,05 4,10 3,50 4,72...
Transcript of ADA 2015 Investor & analyst event Boston, 7 June 2015 · 2020-04-17 · Slide 3 5,05 4,10 3,50 4,72...
Slide 1
5,05
4,10
3,50
4,72
11,82 11,82
ADA 2015
Investor & analyst event
Boston, 7 June 2015
Mexico City – part of Cities Changing Diabetes
Slide 2
5,05
4,10
3,50
4,72
11,82 11,82
Forward-looking statements
Novo Nordisk’s reports filed with or furnished to the US Securities and Exchange Commission (SEC), including this document as well as the company’s Annual Report 2014 and Form 20-F, both filed with the SEC in February 2015, and written information released, or oral statements made, to the public in the future by or on behalf of Novo Nordisk, may contain forward-looking statements. Words such as ‘believe’, ‘expect’, ‘may’, ‘will’, ‘plan’, ‘strategy’, ‘prospect’, ‘foresee’, ‘estimate’, ‘project’, ‘anticipate’, ‘can’, ‘intend’, ‘target’ and other words and terms of similar meaning in connection with any discussion of future operating or financial performance identify forward-looking statements. Examples of such forward-looking statements include, but are not limited to:
• Statements of targets, plans, objectives or goals for future operations, including those related to Novo Nordisk’s products, product research, product development, product introductions and product approvals as well as cooperation in relation thereto
• Statements containing projections of or targets for revenues, costs, income (or loss), earnings per share, capital expenditures, dividends, capital structure, net financials and other financial measures
• Statements regarding future economic performance, future actions and outcome of contingencies such as legal proceedings, and
• Statements regarding the assumptions underlying or relating to such statements.
These statements are based on current plans, estimates and projections. By their very nature, forward-looking statements involve inherent risks and uncertainties, both general and specific. Novo Nordisk cautions that a number of important factors, including those described in this document, could cause actual results to differ materially from those contemplated in any forward-looking statements.
Factors that may affect future results include, but are not limited to, global as well as local political and economic conditions, including interest rate and currency exchange rate fluctuations, delay or failure of projects related to research and/or development, unplanned loss of patents, interruptions of supplies and production, product recall, unexpected contract breaches or terminations, government-mandated or market-driven price decreases for Novo Nordisk’s products, introduction of competing products, reliance on information technology, Novo Nordisk’s ability to successfully market current and new products, exposure to product liability and legal proceedings and investigations, changes in governmental laws and related interpretation thereof, including on reimbursement, intellectual property protection and regulatory controls on testing, approval, manufacturing and marketing, perceived or actual failure to adhere to ethical marketing practices, investments in and divestitures of domestic and foreign companies, unexpected growth in costs and expenses, failure to recruit and retain the right employees, and failure to maintain a culture of compliance.
Please also refer to the overview of risk factors in ‘Be aware of the risk’ on p 42-43 of the Annual Report 2014 on the company’s website novonordisk.com.
Unless required by law, Novo Nordisk is under no duty and undertakes no obligation to update or revise any forward-looking statement after the distribution of this document, whether as a result of new information, future events or otherwise.
Important drug information
• Victoza® (liraglutide 1.2 mg & 1.8 mg) is approved for the management of type 2 diabetes only
• Saxenda® (liraglutide 3 mg) is approved in the US and EU for the treatment of obesity only
ADA 2015 investor and analyst event
Slide 3
5,05
4,10
3,50
4,72
11,82 11,82
Agenda
ADA 2015 investor and analyst event
Time Topic
6.30 pm Welcome – early insights from Saxenda® launch in the US Jesper Brandgaard, CFO
6.35 pm Liraglutide – new data for Saxenda® and Victoza®
Mads Krogsgaard Thomsen, CSO
6.50 pm Faster-acting insulin aspart – controlling postprandial glucose Peter Kurtzhals, SVP Global Research
7.05 pm IDegLira – superior HbA1c reduction with IDegLira compared to insulin glargine Peter Kristensen, SVP Global Development
7.20 pm Discussion and Q&A
Slide 4
5,05
4,10
3,50
4,72
11,82 11,82
0
50
100
150
200
250
16%
43%
41%
Lorcaserin
80% of AOM scripts are still generic
Source: IMS NPA Monthly, Apr 2015
Majority of the anti-obesity medication is generic with new products driving market value expansion
Two latest oral AOM driving branded market expansion
Recent launches increased total AOM market value
ADA 2015 investor and analyst event
0
200
400
600
800
1,000
80%
20%
TRx volume (k)
AOM branded AOM generic
Apr 2015
Apr 2011
0
50
100
150
200
250
300
76%
24%
USD million
AOM branded AOM generic
Apr 2015
Apr 2011
USD million
Naltrexone HCI & bupropion HCI
Phentermine & topiramate
Source: IMS NSP MAT Monthly, Apr 2015 Source: IMS NSP MAT Monthly, Apr 2015
Apr 2015
Apr 2011
Slide 5
5,05
4,10
3,50
4,72
11,82 11,82
8,430
3,989
1,204
816
0
2,000
4,000
6,000
8,000
10,000
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
• Encouraging initial Saxenda® uptake
• Positive early feedback from physicians and patients
• Limited formulary access primarily with prior authorisation
• Expanding formulary access remains a main priority
Note: IMS reporting for new launches may reflect data instability due to small volume and/or supplier reporting Source: IMS NPA TRx, Weekly data
AOM launch uptake Key launch observations
Encouraging early script development for Saxenda®
ADA 2015 investor and analyst event
TRx volume
Weeks from launch
Saxenda®
Lorcaserin
Phentermine & topiramate
Naltrexone HCI & bupropion HCI
Slide 6
5,05
4,10
3,50
4,72
11,82 11,82
Liraglutide – new data for Saxenda® and Victoza®
Mads Krogsgaard Thomsen
EVP & Chief Science Officer
ADA 2015 investor and analyst event
Slide 7
5,05
4,10
3,50
4,72
11,82 11,82
SCALE™ obesity and prediabetes: design of the largest clinical trial conducted within obesity
Note: *Treated or untreated hypertension or dyslipidaemia according to ATP-III; **Treatment ends at week 68 for the non-prediabetic population and is proceeded by an off-treatment follow-up period of 2 weeks. ClinicalTrials.gov. Identifier: NCT01272219 Source: Wilding et al. ADA 2015. Poster number 2229
ADA 2015 investor and analyst event
Screening
0.6 mg 1.2 mg
1.8 mg
2.4 mg
Liraglutide 3 mg
Placebo
Dose escalation
Liraglutide 3 mg
Placebo
Liraglutide 3 mg
Placebo
Non- prediabetic
Prediabetic
0.6 mg
1.2 mg 1.8 mg
2.4 mg Observational follow-up
Follow-up
0 4 160 Week −2 172 70 68 56
3,731 people with:
• BMI: ≥30 or (≥27+ comorbidities*)
• Stable body
weight &
preceding failed
dietary effort
Randomisation: 2:1 EOTT EOS** EOS
Re-randomisation: 1:1
Lifestyle intervention: -500 kcal/day hypo caloric diet + increased physical activity
Slide 8
5,05
4,10
3,50
4,72
11,82 11,82
Number of participants in different categories for Saxenda® and placebo after 56 weeks
Reversal of prediabetes in early responders who completed 56 weeks of treatment
The majority of early Saxenda® responders lost ≥5% or >10% weight and reversed prediabetes in SCALE™ trial
1 Participants losing ≥4% body weight at week 16 with prediabetes and completing 56 weeks treatment * Percentage of people with prediabetes; ** Percentage of completed early responders
Source: Wilding et al. ADA 2015. Poster number 2229 Source: Wilding et al. ADA 2015. Poster number 2229
Saxenda® Placebo
2,487
1,528
905 (59%*)
765 (85%**)
431 (48%**)
1,244
757
165 (22%*)
114 (69%**)
55 (33%**)
Saxenda® Placebo
Randomised
With prediabetes
Completed early responders1
Completed early responders with ≥5% weight loss
Completed early responders with >10% weight loss
ADA 2015 investor and analyst event
76.9 82.8
46.5
58.2
0
20
40
60
80
100
Pro
po
rti
on
of
parti
cip
an
ts (
%)
Participants achieving ≥5% weight loss
Participants achieving >10% weight loss
Slide 9
5,05
4,10
3,50
4,72
11,82 11,82
SCALE™ obesity and prediabetes: 3 years trial design
Note: * Treated or untreated hypertension or dyslipidaemia according to ATP-III; **Treatment ends at week 68 for the non-prediabetic population and is proceeded by an off-treatment follow-up period of 2 weeks. ClinicalTrials.gov. Identifier: NCT01272219 Source: Pi-Sunyer et al. AACE. 2014. Abstract number: 700
ADA 2015 investor and analyst event
Screening
0.6 mg 1.2 mg
1.8 mg
2.4 mg
Liraglutide 3 mg
Placebo
Dose escalation
Liraglutide 3 mg
Placebo
Liraglutide 3 mg
Placebo
Non- prediabetic
Prediabetic
0.6 mg
1.2 mg 1.8 mg
2.4 mg Observational follow-up
Follow-up
0 4 160 Week −2 172 70 68 56
3,731 people with:
• BMI: ≥30 or (≥27+ comorbidities*)
• Stable body
weight &
preceding failed
dietary effort
Randomisation: 2:1 EOTT EOS** EOS
Re-randomisation: 1:1
Lifestyle intervention: -500 kcal/day hypo caloric diet + increased physical activity
Slide 10
5,05
4,10
3,50
4,72
11,82 11,82
• Approximately 80% reduced risk of developing T2D for people treated with Saxenda®3
• At 160-week, completion rate of 53% and 45% for Saxenda® and placebo respectively
• Saxenda® appeared to have a safe and well tolerated profile and most frequently reported adverse events were gastrointestinal in nature
1 p<0.0001. 2 p<0.0001 Source: Pi-Sunyer et al. AACE. 2014. Abstract number: 700; Novo Nordisk data on file (NN8022-1839)
Sustained weight loss with Saxenda® SCALETM
obesity and prediabetes trial Saxenda® effect on emerging type 2 diabetes
After three years of treatment Saxenda® shows sustained weight loss and reduced risk of type 2 diabetes vs placebo in SCALE™ trial
3 p<0.0001 Source: Novo Nordisk data on file (NN8022-1839)
ADA 2015 investor and analyst event
Saxenda® (placebo) 56 weeks1
Saxenda®
(placebo) 160 weeks2
Mean weight reduction
8% (3%) 6% (2%)
Proportion achieving 5% weight reduction
63% (27%) 50% (23%)
Proportion achieving 10% weight reduction
33% (11%) 24% (9%)
Slide 11
5,05
4,10
3,50
4,72
11,82 11,82
89
90
91
92
93
94
95
96
97
98
99
100
0 8 16 24 32 40 48 56 64 72 80 88 96 104 112 120 128 136 144 152 160 168
Time to onset of T2D up to 160 weeks of treatment estimated survival time
Note: Time of onset of T2D occurs between first of two required registrations of elevated HbA1c, FPG or 2 hour oral glucose tolerance test plasma glucose, and the diabetes assessment visit prior to first registration. The estimated survival time is based on an analysis of time to onset of T2D analysed in a Weibull model including treatment, gender and BMI stratification factor as fixed factors and baseline FPG as covariate. Output presents data for subjects with prediabetes at baseline and includes 6 subjects who did not have prediabets at baseline, but participated in the extension period of the trial. Source: Weibull analysis, FAS
Saxenda® treatment increases time to onset of type 2 diabetes vs placebo in 3-years SCALETM trial – For each 14 patients treated with Saxenda® for three years one case of diabetes is prevented
ADA 2015 investor and analyst event
Time since randomisation (weeks)
Su
bje
cts
no
t d
iag
no
sed
w
ith
TD
2 (
%)
Saxenda® Placebo
factor=2.6
0
Slide 12
5,05
4,10
3,50
4,72
11,82 11,82
• Metformin can be used safely
• SUs should be used with caution due to inherent risk of
hypoglycaemia
• GLP-1s might be associated with a low risk of hypoglycaemia
in addition to their potent effect on glycaemic control and
bodyweight
Source: The world factbook on www.cia.gov/library/publications/the-world-factbook; The Future Global Muslim Population Projections for 2010-2030. Pew Research Center; IDF Diabetes Atlas 2014
Around 100 million Muslims estimated to have type 2 diabetes ADA recommendations during Ramadan
Practicing muslims with type 2 diabetes could benefit from GLP-1 during Ramadan but limited clinical data has existed
Source: Al-Arouj M et al. Diabetes Care 2010;33(8):1895–1902
ADA 2015 investor and analyst event
Muslim population: 1.7 billion
Adults with T2D: 387 million
Global population: 7.2 billion
Slide 13
5,05
4,10
3,50
4,72
11,82 11,82
Overall results: • Victoza® was associated with a significantly larger reduction
in HbA1c and body weight compared with SU1
• A significantly lower risk of confirmed hypoglycaemia was observed with Victoza® vs SU2
During Ramadan: • Victoza® was associated with a similar reduction in
fructosamine compared with SU
• Numerically fewer hypoglycaemic episodes were seen with Victoza® vs SU despite better glycaemic control
1 Inclusion criteria: Type 2 diabetes, BMI 20 kg/m2, HbA1c 7–10%, on metformin 1000 mg/day and SU 90 days and intent to fast during Ramadan * Ramadan lasts between 29-30 days
Source: Azar et al. ADA 2015. Poster number 1121
Trial design Key trial results
Randomised clinical trial investigating ability of Victoza® to improve glycaemic control during Ramadan
1 p<0.001; 2 p=0.0027 Fructosamine: glycated serum protein reflecting glycaemic control for the previous 2−3 weeks Source: Azar et al. ADA 2015. Poster number 1121
ADA 2015 investor and analyst event
SU + metformin
Victoza® + metformin
Dose escalation
341 people with type 2 diabetes1
0 -2
Screening Treatment
maintenance Ramadan
Post Ramadan
3-4 6-9 4* 4* Week
Slide 14
5,05
4,10
3,50
4,72
11,82 11,82
Faster-acting insulin aspart – controlling postprandial
glucose Peter Kurtzhals
SVP Global Research
ADA 2015 investor and analyst event
Slide 15
5,05
4,10
3,50
4,72
11,82 11,82
Sustained Insulin profile (basal)
The aim of insulin therapy is to recreate normal blood insulin profile
Faster-acting insulin approaching physiological insulin profile even further
Unmet medical need for a faster-acting insulin approaching physiological insulin profile and with better pump profile
Source: Polonsky KS et al. N Engl J Med 1988;318:1231–1239 * Schematic representation
ADA 2015 investor and analyst event
Time (h)
In
su
lin
acti
on
(at
mealt
ime)
*
Human insulin
Faster-acting insulin
Fast acting insulin
Pancreas release
6:00 0
10
20
30
40
50
60
70
10:00 14:00 18:00
Insulin (mU/L)
22:00 2:00 6:00
Short-lived, rapidly generated meal-related peaks (prandial)
Time of day
Breakfast Lunch Dinner
Slide 16
5,05
4,10
3,50
4,72
11,82 11,82
Elements influencing postprandial glucose (PPG)
In diabetes, PPG depends on early insulin appearance and action on the liver and peripheral tissues after a meal
ADA 2015 investor and analyst event
Process 2
Process 3
Add text
Action on the liver Peripheral tissues after a meal
Early insulin appearance
Slide 17
5,05
4,10
3,50
4,72
11,82 11,82
75% 62%
25% 38%
0%
20%
40%
60%
80%
100%
Healthy Type 2 Diabetes
Hepatic glucose release drives overall higher PPG release in T2D patients
Hepatic glucose production accounts for larger part of PPG in T2D vs healthy people
Need for a faster-acting insulin to reduce hepatic glucose production around meal
Source: Woerle HJ et al. Am J Physiol Endocrinol Metab 2006;290:E67–E77 Source: Woerle HJ et al. Am J Physiol Endocrinol Metab 2006;290:E67–E77
ADA 2015 investor and analyst event
59 61
19
37
0
20
40
60
80
100
120
Healthy Type 2 diabetes
PPG release over 6-hours (g)
Meal-related glucose Hepatic glucose Meal-related glucose Hepatic glucose
Slide 18
5,05
4,10
3,50
4,72
11,82 11,82
-2
0
2
4
6
8
-60 0 60 120 180 240
Faster-acting insulin aspart shows higher plasma glucose reduction in meal test
Greater glucose-lowering after meal with faster-acting insulin aspart
Faster-acting insulin aspart shows higher glucose reduction in phase 1 trial
Source: Bode et al ADA 2015. Poster number: 994
* p<0.05
Source: Bode et al ADA 2015. Poster number: 994
ADA 2015 investor and analyst event
Faster-acting insulin aspart vs insulin aspart
Change in plasma glucose following meal test after 14 days
ΔPGav,0–1h, mmol/L –0.50 [–1.07; 0.07]
ΔPGav,0–2h, mmol/L –0.99* [–1.95; –0.03]
Baselin
e a
dju
ste
d p
lasm
a
glu
co
se (
mm
ol/
L)
Nominal time (min)
Insulin aspart Faster-acting insulin aspart
Slide 19
5,05
4,10
3,50
4,72
11,82 11,82
• Greater improvement of HbA1c with mealtime faster-acting insulin aspart compared to NovoRapid®
• Similar HbA1c improvement with faster-acting insulin aspart when dosed post-meal and NovoRapid®
• Statistically larger improvements in 1- and 2-hour PPG increments with meal-time faster-acting insulin aspart
• Similar overall rate of hypoglycaemia for all treatment groups, with a higher rate within first hour after meal with faster-acting insulin aspart if dosed at mealtime
• Previously reported safety and tolerability profiles of insulin aspart confirmed
1 Inclusion criteria: Type 1 diabetes, optimised on Levemir®. 1,143 people randomised
MT: Mealtime; PM: Post-meal Source: Novo Nordisk data on file (NN1218-3852 T1D)
onset® 1 trial design Headline results
Faster-acting insulin aspart shows additional improvement of HbA1c vs NovoRapid® in phase 3 trial onset® 1
ADA 2015 investor and analyst event
Faster-acting insulin aspart
(PM)
Faster-acting insulin aspart (MT)
NovoRapid® (MT)
52 weeks
26
-8 0 Run-in
1,290 people with type 1 diabetes1
Source: Novo Nordisk data on file (NN1218-3852 T1D)
Slide 20
5,05
4,10
3,50
4,72
11,82 11,82
• Similar reduction of HbA1c in both treatment groups
• Statistically larger improvement in 1-hour PPG increment with faster-acting insulin aspart and numerically larger reduction for 2-hour PPG increment
• Similar overall rate of hypoglycaemia, with a higher rate of hypoglycaemia for faster-acting insulin aspart within first two hours after meal
• Previously reported safety and tolerability profiles of insulin aspart confirmed
1 Inclusion criteria: Type 2 diabetes, optimised on basal insulin and OAD; HbA1c of 7.5-9.5%. 689 people randomised
MT: Mealtime Source: Novo Nordisk data on file (NN1218-3853 T2D)
onset® 2 trial design Headline results
Faster-acting insulin aspart shows larger improvement in 1-hour postprandial glucose vs NovoRapid® in phase 3 trial
ADA 2015 investor and analyst event
881 people with type 2 diabetes1
Faster-acting insulin aspart (MT)
NovoRapid® (MT)
26 weeks
-8 0 Run-in
Source: Novo Nordisk data on file (NN1218-3853 T2D)
Slide 21
5,05
4,10
3,50
4,72
11,82 11,82
IDegLira – superior HbA1c reduction with IDegLira
compared to insulin glargine
ADA 2015 investor and analyst event
Peter Kristensen
SVP Global Development
Slide 22
5,05
4,10
3,50
4,72
11,82 11,82
Remaining IDegLira phase 3 data shown at this year’s ADA
Phase 3a trials Phase 3b trials
2011 2012 2013 2014
DUAL™ I: IDegLira vs individual components, 26 weeks, n=1,660
26-week extension
DUAL™ II: IDegLira vs IDeg, n=400
DUAL™ III: Switch from GLP-1 therapy, 26 weeks, n=429
DUAL™ IV: Add-on to SU, 26 weeks, n=435
DUAL™ V: IDegLira vs IGlar, 26 weeks, n=554
Note: Timing of trials as listed on www.clinicaltrials.gov excl. data analysis
ADA 2015 investor and analyst event
Oral: ADA 2014
Oral: ADA 2014
Oral: ADA 2015
Data presentation
Poster: ADA 2015
Poster: ADA 2015
Slide 23
5,05
4,10
3,50
4,72
11,82 11,82
Trial design Baseline characteristics
DUAL™ V phase 3 trial investigating IDegLira vs insulin glargine in people with type 2 diabetes
1 Inclusion criteria: Type 2 diabetes, insulin glargine (20–50 units) + metformin, 7%≤ HbA1c ≤10%, Age ≥18 years, BMI ≤40 kg/m2 Note: IDegLira starting dose: 16 dose steps; max dose: 50 dose steps. Insulin glargine starting dose: pre-trial dose; max dose: none Source: Buse et al. ADA 2015. Oral number 166 Source: Buse et al. ADA 2015. Oral number 166
IDegLira IGlar
Mean age (years) 58.4 59.1
Mean diabetes duration (years)
11.6 11.3
Mean BMI (kg/m2) 31.7 31.7
Mean HbA1c 8.4% 8.2%
Mean FPG (mmol/L) 8.9 8.9
Mean pre-trial insulin glargine dose
31 32
IGlar + metformin
IDegLira + metformin
26 weeks
557 people with type 2 diabetes1
0 -2
Run-in open label, 1:1 randomisation
ADA 2015 investor and analyst event
Slide 24
5,05
4,10
3,50
4,72
11,82 11,82
5.5
6.0
6.5
7.0
7.5
8.0
8.5
9.0
90
100
110
120
130
140
150
160
170
5.0
5.5
6.0
6.5
7.0
7.5
8.0
8.5
9.0
9.5
Statistically significantly higher reduction of HbA1c with IDegLira vs IGlar
Both patient groups achieved similar FBG at the end of trial
IDegLira associated with superior HbA1c reduction compared with insulin glargine in DUAL™ V
* p<0.001; mean observed values FAS and LOCF imputed data; treatment difference ANCOVA analysis; ∆ values observed LOCF. No maximum dose for IGlar Source: Buse et al. ADA 2015. Oral number 166
Note: Mean observed values FAS and LOCF imputed data Source: Buse et al. ADA 2015. Oral number 166
ADA 2015 investor and analyst event
7.1% ∆: -1.13
HbA1c (%)
0.0
6.6% ∆: −1.81
* FP
G (
mm
ol/
L)
Time (weeks) 26 0
IDegLira IGlar IDegLira IGlar
0.0
Time (weeks) 26 0
6.1 mmol/L (110.2 mg/dL)
6.1 mmol/L (109.5 mg/dL)
0
FP
G (
mg
/d
L)
Slide 25
5,05
4,10
3,50
4,72
11,82 11,82
-2.0
-1.5
-1.0
-0.5
0.0
0.5
1.0
1.5
2.0
0
10
20
30
40
50
60
70
Time (weeks)
Statistically significant mean weight difference of -3.2kg for IDegLira vs IGlar
Patients treated with IDegLira in DUAL™ V require lower insulin dose and achieve weight loss vs insulin glargine
* p<0.001; mean observed values FAS and LOCF imputed data; treatment difference ANCOVA analysis; ∆ values observed LOCF. No maximum dose for IGlar Source: Buse et al. ADA 2015. Oral number 166
* p<0.001; mean observed values FAS and LOCF imputed data; treatment difference ANCOVA analysis; ∆ values observed LOCF Source: Buse et al. ADA 2015. Oral number 166
Insulin dose units
kg
Statistically significantly fewer insulin units used by patients treated with IDegLira vs IGlar
66 units
41 units
*
89.1 kg ∆: +1.8
86.9 kg ∆: −1.4
*
ADA 2015 investor and analyst event
Time (weeks) 26 0 26 0
IDegLira IGlar IDegLira IGlar
Slide 26
5,05
4,10
3,50
4,72
11,82 11,82
Statistically significantly lower rate of confirmed hypoglycaemia with IDegLira vs IGlar
Statistically significantly lower rate of confirmed nocturnal hypoglycaemia with IDegLira vs IGlar
IDegLira associated with lower rates of confirmed and nocturnal hypoglycaemia vs insulin glargine in DUAL™ V
* p<0.001; mean observed values FAS and LOCF imputed data; treatment difference ANCOVA analysis; ∆ values observed LOCF. No maximum dose for IGlar. Confirmed hypoglycaemia was defined as severe or <56 mg/dL Source: Buse et al. ADA 2015. Oral number 166
* p<0.001; mean observed values FAS and LOCF imputed data; treatment difference ANCOVA analysis; ∆ values observed LOCF. No maximum dose for IGlar. Confirmed severe or <56 mg/dL; Nocturnal between 00:01–05:59 (both inclusive) Source: Buse et al. ADA 2015. Oral number 166
0.0
0.5
1.0
1.5
2.0
2.5
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
Number of episodes per subject
Number of episodes per subject
*
*
ADA 2015 investor and analyst event
Time (weeks) Time (weeks)
Treatment ratio: 0.43
Treatment ratio: 0.17
26 0 26 0
IDegLira IGlar IDegLira IGlar
Slide 27
5,05
4,10
3,50
4,72
11,82 11,82
71.6
54.3 50.0 38.8
47.0
29.4 19.7
12.2 0
10
20
30
40
50
60
70
80
Few patients experience nausea when treated with IDegLira
Proportion of subjects achieving HbA1c <7% and composite endpoints with IDegLira vs IGlar
More patients treated with IDegLira achieve treatment targets vs insulin glargine in DUAL™ V
Source: Buse et al. ADA 2015. Oral number 166. Data are from safety analysis set
* p<0.001. Responders are based on FAS and LOCF inputed data Source: Buse et al. ADA 2015. Oral number 166
ADA 2015 investor and analyst event
Proportions of subjects (%)
IDegLira IGlar
HbA1c<7% HbA1c<7% w/o weight gain
HbA1c<7% w/o hypoglycaemia
HbA1c<7% w/o hypoglycaemia & weight gain
*
*
*
*
0
2
4
6
8
10
IDegLira IGlar Frequency (%)
Time (weeks) 26 0
Slide 28
5,05
4,10
3,50
4,72
11,82 11,82
Concluding remarks
ADA 2015 investor and analyst event
3-year treatment with Saxenda® reduces risk of type 2 diabetes by 80% compared with placebo in SCALE ™ trial
Encouraging initial uptake of Saxenda® in the US but formulary access remains the key challenge
Victoza® has the ability to improve glycaemic control during Ramadan as documented in clinical trial
Faster-acting insulin aspart shows improved glycaemic control vs NovoRapid® in phase 3 trials
IDegLira shows superiority vs IGlar in DUAL™ V with a HbA1c reduction of 1.8% and a 3.2 kg weight benefit
Slide 29
5,05
4,10
3,50
4,72
11,82 11,82
Jesper Brandgaard, EVP & CFO
Mads Krogsgaard Thomsen, EVP & CSO
Peter Kurtzhals, SVP Global Research
Peter Kristensen, SVP Global Development
ADA 2015 investor and analyst event
Slide 30
5,05
4,10
3,50
4,72
11,82 11,82
Share information Investor Relations contacts
Investor contact information
Novo Nordisk’s B shares are listed on the stock exchange in Copenhagen under the symbol ‘NOVO B’. Its ADRs are listed on the New York Stock Exchange under the symbol ‘NVO’. For further company information, visit Novo Nordisk on the internet at: novonordisk.com
Kasper Roseeuw Poulsen +45 3079 4303 [email protected]
Daniel Bohsen +45 3079 6376 [email protected]
Melanie Raouzeos +45 3075 3479 [email protected]
In North America:
Frank Daniel Mersebach
+1 609 235 8567
Novo Nordisk A/S Investor Relations Novo Allé, DK-2880 Bagsværd
06 Aug 2015 Financial statement for the first six months of 2015
29 Oct 2015 Financial statement for the first nine months of 2015
03 Feb 2016 Financial statement for 2015
Upcoming events
ADA 2015 investor and analyst event
Slide 31
5,05
4,10
3,50
4,72
11,82 11,82
Appendix – Glossary
ADA 2015 investor and analyst event
Abbreviation Meaning Abbreviation Meaning Abbreviation Meaning
ADA American Diabetes Association FAS Fasting plasma glucose LOCF Last observation carried forward
ANCOVA Analysis of covariance GIR Glucose infusion rate PG Plasma glucose
AOM Anti-obesity medication GLP-1 Glucagon-like peptide-1 PPG Postprandial glucose
BMI Body mass index (kg/m2) HbA1c Glycated haemoglobin A1c TRx Total prescriptions
EOS End of study IAsp Insulin aspart T2D Type 2 diabetes
EOTT End of treatment IDeg Insulin degludec SU Sulfonylurea
FAS Full analysis set IGlar Insulin glargine